Evaluation of Total Hepatocellular Cancer Lifespan, Including Both Clinically Evident and Preclinical Development, Using Combined Network Phenotyping Strategy and Fisher Information Analysis
Abstract
We previously showed that for hepatocellular cancer (HCC) prognostication, disease parameters need to be considered within a total personal clinical context. This requires preserving the coherence of data values, observed simultaneously for each patient during baseline diagnostic evaluation.
Application of the Network Phenotyping Strategy (NPS) provided quantitative descriptors of these patient coherences. Combination of these descriptors with Fisher information about the patient tumor mass and the histogram of the tumor masses in the whole cohort permitted estimation of the time from disease onset until clinical diagnosis (t(baseline)).
We found faster growth of smaller tumors having total masses 70. Combining the clinical survival and tbasth normalized all HCC patients to a common 1,045 days of mean total disease duration (t(baseline) plus post diagnosis survival).
We also found a simple relationship between the baseline clinical status, t(baseline) and survival. Every difference between individual patient baseline clinical profiles and special coherent clinical status (HL1) reduced the above common overall survival (OVS) by 65 days.
In summary, we showed that HCC patients with any given tumor can best have their tumor biology understood, when account is taken of the total clinical and liver contexts, and with knowing the point in the tumor history when an HCC diagnosis is made. This ability to compute the t(baseline) from standard clinical data brings us closer to calculating survival from diagnosis of individual HCC patients.